Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention

被引：11

作者：

Kim, Yeon-Sook ^{[1
]}

机构：

[1] Chungnam Natl Univ, Div Infect Dis, Dept Internal Med, Sch Med, 282 Munhwa Ro, Daejeon 35015, South Korea

来源：

INFECTION AND CHEMOTHERAPY | 2021年 / 53卷 / 04期

关键词：

Human immunodeficiency virus; Long-acting; Injectable antiretroviral agents; Pre-exposure prophylaxis; PHASE; 2B; NAIVE ADULTS; CABOTEGRAVIR; RILPIVIRINE; ANTIPSYCHOTICS; SCHIZOPHRENIA; INHIBITORS; THERAPY;

D O I：

10.3947/ic.2021.0136

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.

引用

页码：686 / 695

页数：10

共 50 条

[31] Interest of people living with HIV in injectable long-acting antiretroviral treatment: results from a flash AIDES survey
Lacoux, C.
Rouquette, C.
Salcedo, M.
Alain, T.
Le Gouez, C.
Michels, D.
Spire, B.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 36 - 37
[32] Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection
D'Amico, Ronald
Margolis, David A.
[J]. CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 13 - 18
[33] Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection
不详
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (20) : 1842 - 1843
[34] Longitudinal immunophenotyping analysis of peripheral blood cells in PLWH on long-acting injectable HIV antiretroviral
Zingaropoli, M. A.
Carraro, A.
Guardiani, M.
Tortellini, E.
Dominelli, F.
Falvino, C.
Ngangue, Y. C. Fosso
Garattini, S.
Zuccala, P.
Marocco, R.
Del Borgo, C.
Lichtner, M.
[J]. HIV MEDICINE, 2023, 24 : 391 - 391
[35] Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
Koester K.A.
Colasanti J.A.
McNulty M.C.
Dance K.
Erguera X.A.
Tsuzuki M.D.
Johnson M.O.
Sauceda J.A.
Montgomery E.
Schneider J.
Christopoulos K.A.
[J]. Implementation Science Communications, 4 (1):
[36] Long-acting rilpivirine for HIV prevention
Jackson, Akil
McGowan, Ian
[J]. CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 253 - 257
[37] Long-acting drugs and formulations for the treatment and prevention of HIV infection
Flexner, Charles
Owen, Andrew
Siccardi, Marco
Swindells, Susan
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (01)
[38] Long-acting injectable for HIV approved for use in the UK
Kirby, Tony
[J]. LANCET INFECTIOUS DISEASES, 2022, 22 (01): : 26 - 26
[39] Long-acting injectable ART: next revolution in HIV?
Boyd, Mark A.
Cooper, David A.
[J]. LANCET, 2017, 390 (10101): : 1468 - 1470
[40] M Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
Landovitz, Raphael J.
Grinsztejn, Beatriz
[J]. JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (10): : 1519 - 1520

← 1 2 3 4 5 →